LUGANO (AIMnews.it) - Continuous research is the added value for Kolinpharma. "Listing on AIM - explains Emanuele Lusenti, managing director of the company - has favoured investments on this axis, which for us represents a strategic priority. H2020 has also contributed to realising important research projects, which enjoy certificates of excellence". The company, among the protagonists of the 9th Lugano IR Top Investor Day, is ready to open up for collaborations with foreign companies. "The production - adds Lusenti - remains Italian, the skills we need are here, but we want to be present in person in the territories we work with."
